127 related articles for article (PubMed ID: 35470464)
1. The role of the genetic variant FECH rs11660001 in the occurrence of anti-tuberculosis drug-induced liver injury.
Zhang M; Zhu J; Wang N; Liu W; Lu L; Pan H; He X; Yi H; Tang S
J Clin Pharm Ther; 2022 Aug; 47(8):1276-1283. PubMed ID: 35470464
[TBL] [Abstract][Full Text] [Related]
2. Association between NR1I2 polymorphisms and susceptibility to anti-tuberculosis drug-induced hepatotoxicity in an Eastern Chinese Han population: A case-control study.
Yang M; Pan H; Chen H; Liu W; Lu L; He X; Yi H; Tang S
Infect Genet Evol; 2020 Sep; 83():104349. PubMed ID: 32387752
[TBL] [Abstract][Full Text] [Related]
3. Possible association of HMOX1 and NQO1 polymorphisms with anti-tuberculosis drug-induced liver injury: A matched case-control study.
Yang M; Zhang H; Tao B; Pan H; Lu L; Yi H; Tang S
J Clin Pharm Ther; 2019 Aug; 44(4):534-542. PubMed ID: 30776144
[TBL] [Abstract][Full Text] [Related]
4. A validation study of the UGT1A4 rs2011404 variant and the risk of anti-tuberculosis drug-induced hepatotoxicity in an Eastern Chinese Han population.
Zhu J; Liu W; Zhang M; Lu L; Pan H; He X; Wang N; Yang M; Yi H; Tang S
J Clin Pharm Ther; 2021 Oct; 46(5):1288-1294. PubMed ID: 34046917
[TBL] [Abstract][Full Text] [Related]
5. Glutamate dehydrogenase combined with ferrochelatase as a biomarker of liver injury induced by antituberculosis drugs.
He B; Cheng X; Xiang HR; Li Y; Zhang QZ; Peng WX; Yang B
Br J Clin Pharmacol; 2023 Oct; 89(10):3092-3104. PubMed ID: 37259680
[TBL] [Abstract][Full Text] [Related]
6. Association between genetic polymorphisms of NRF2, KEAP1, MAFF, MAFK and anti-tuberculosis drug-induced liver injury: a nested case-control study.
Chen S; Pan H; Chen Y; Lu L; He X; Chen H; Chen R; Zhan S; Tang S
Sci Rep; 2019 Oct; 9(1):14311. PubMed ID: 31586142
[TBL] [Abstract][Full Text] [Related]
7. Association of ABO blood group and antituberculosis drug-induced liver injury: A case-control study from a Chinese Han population.
Tao B; Yang M; Chen H; Pan H; Liu W; Yi H; Tang S
J Clin Pharm Ther; 2020 Aug; 45(4):638-645. PubMed ID: 32259340
[TBL] [Abstract][Full Text] [Related]
8. The Isoniazid Metabolites Hydrazine and Pyridoxal Isonicotinoyl Hydrazone Modulate Heme Biosynthesis.
Brewer CT; Yang L; Edwards A; Lu Y; Low J; Wu J; Lee RE; Chen T
Toxicol Sci; 2019 Mar; 168(1):209-224. PubMed ID: 30517741
[TBL] [Abstract][Full Text] [Related]
9. Association of POR and PPARα polymorphisms with risk of anti-tuberculosis drug-induced liver injury in Western Chinese Han population.
Zhang C; Jiao L; Bai H; Zhao Z; Hu X; Wang M; Wu T; Peng W; Liu T; Song J; Zhou J; Li M; Lyv M; Zhang J; Chen H; Chen J; Ying B
Infect Genet Evol; 2020 Apr; 79():104147. PubMed ID: 31857256
[TBL] [Abstract][Full Text] [Related]
10. Involvement of protoporphyrin IX accumulation in the pathogenesis of isoniazid/rifampicin-induced liver injury: the prevention of curcumin.
He L; Guo Y; Deng Y; Li C; Zuo C; Peng W
Xenobiotica; 2017 Feb; 47(2):154-163. PubMed ID: 28118809
[TBL] [Abstract][Full Text] [Related]
11. Do genetic polymorphisms of B-cell CLL/lymphoma 2 confer susceptibility to anti-tuberculous therapy-associated drug-induced liver injury?
Lyu M; Jiao L; Zhou J; Li H; Meng Z; Xie W; Ren J; Bian Q; Ying B
Int J Infect Dis; 2020 Feb; 91():223-231. PubMed ID: 31838216
[TBL] [Abstract][Full Text] [Related]
12. NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients.
Wattanapokayakit S; Mushiroda T; Yanai H; Wichukchinda N; Chuchottawon C; Nedsuwan S; Rojanawiwat A; Denjanta S; Kantima T; Wongyai J; Suwankesawong W; Rungapiromnan W; Kidkeukarun R; Bamrungram W; Chaiwong A; Suvichapanich S; Mahasirimongkol S; Tokunaga K
Int J Tuberc Lung Dis; 2016 Oct; 20(10):1364-1369. PubMed ID: 27725049
[TBL] [Abstract][Full Text] [Related]
13. The association between HLA-DQB1 polymorphism and antituberculosis drug-induced liver injury: a Case-Control Study.
Chen R; Zhang Y; Tang S; Lv X; Wu S; Sun F; Xia Y; Zhan SY
J Clin Pharm Ther; 2015 Feb; 40(1):110-5. PubMed ID: 25250564
[TBL] [Abstract][Full Text] [Related]
14. Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients.
Chan SL; Chua APG; Aminkeng F; Chee CBE; Jin S; Loh M; Gan SH; Wang YT; Brunham LR
PLoS One; 2017; 12(10):e0186200. PubMed ID: 29036176
[TBL] [Abstract][Full Text] [Related]
15. NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis.
Yuliwulandari R; Susilowati RW; Wicaksono BD; Viyati K; Prayuni K; Razari I; Kristin E; Syafrizal ; Subagyo ; Sri Diana E; Setiawati S; Ariyani A; Mahasirimongkol S; Yanai H; Mushiroda T; Tokunaga K
J Hum Genet; 2016 Jun; 61(6):533-7. PubMed ID: 26911349
[TBL] [Abstract][Full Text] [Related]
16. Association of LEPR polymorphisms with predisposition and inflammatory response in anti-tuberculosis drug-induced liver injury: A pilot prospective investigation in Western Chinese Han population.
Zhao Z; Peng W; Zhou J; Zhou Y; Liu T; Bai H; Wu Q; Song J; Wu L; Song X; Ying B
Infect Genet Evol; 2019 Nov; 75():103970. PubMed ID: 31325611
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms of NAT2, CYP2E1, GST, and HLA related to drug-induced liver injury in indonesian tuberculosis patients.
Perwitasari DA; Darmawan E; Mulyani UA; Vlies PV; Alffenaar JC; Atthobar J; Wilffert B
Int J Mycobacteriol; 2018; 7(4):380-386. PubMed ID: 30531039
[TBL] [Abstract][Full Text] [Related]
18. CYP7A1, BAAT and UGT1A1 polymorphisms and susceptibility to anti-tuberculosis drug-induced hepatotoxicity.
Chen R; Wang J; Tang SW; Zhang Y; Lv XZ; Wu SS; Yang ZR; Xia YY; Chen DF; Zhan SY
Int J Tuberc Lung Dis; 2016 Jun; 20(6):812-8. PubMed ID: 27155186
[TBL] [Abstract][Full Text] [Related]
19. The A/A Genotype of XPO1 rs4430924 Is Associated With Higher Risk of Antituberculosis Drug-Induced Hepatotoxicity in Chinese Patients.
He X; Zhang H; Tao B; Yang M; Chen H; Lu L; Yi H; Pan H; Tang S
J Clin Pharmacol; 2019 Jul; 59(7):1014-1021. PubMed ID: 30817003
[TBL] [Abstract][Full Text] [Related]
20. Association of FAM65B, AGBL4, and CUX2 genetic polymorphisms with susceptibility to antituberculosis drug-induced hepatotoxicity: validation study in a Chinese Han population.
Pan H; Yang M; Lu L; Tao B; He X; Chen H; Yi H; Tang S
Pharmacogenet Genomics; 2019 Jun; 29(4):84-90. PubMed ID: 30720667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
